Lipid metabolism regulatory genes

Lipid metabolism regulatory genes encompass a wide array of genetic components that encode proteins responsible for the biosynthesis, catabolism, and trafficking of lipids. This heterogeneous group includes key metabolic enzymes such as HMG-CoA reductase (HMGCR), nuclear receptors like Peroxisome Proliferator-Activated Receptors (PPARs), and specialized transporters like the Low-Density Lipoprotein Receptor (LDLR) (StatPearls, 2023). These genes play a fundamental role in maintaining systemic cholesterol levels, fatty acid balance, and energy homeostasis within various tissues, particularly the liver and adipose tissue. When the expression or function of these genes is disrupted, it leads to conditions such as hypercholesterolemia, obesity, and cardiovascular diseases (PubMed, 2024). In clinical medicine, these genes are leveraged as a framework for identifying therapeutic targets to manage metabolic syndromes. Well-established pharmacological interventions target specific proteins within this category, such as statins for HMGCR and fibrates for PPAR-alpha. Additionally, emerging therapies like PCSK9 inhibitors further demonstrate the clinical importance of targeting the proteins encoded by these regulatory genes. Because the term refers to a functional class of genes rather than a single molecular entity, it is primarily used in research to describe polygenic influences on lipid profiles rather than a specific drug target (NIH, 2023).

Other names

Lipid metabolic genesLipid metabolism-related genesGenes regulating lipid metabolismLipid homeostasis genes

Pharmacological mechanisms targeting this gene class include HMG-CoA reductase inhibition (statins), PPAR-alpha activation (fibrates), PCSK9 inhibition (monoclonal antibodies), and NPC1L1 inhibition (ezetimibe).